ArticleFrontiers in medicine2025
Effects of a community pharmacy-based structured medication review on drug-related problems in all-comers with polypharmacy: a randomized, controlled, double-blind, parallel-group trial.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Medication reviews may help to reduce the burdens of polypharmacy. A medication review type 2a is a structured evaluation of a patient's pharmacotherapy based on medication history and patient information in a face-to-face interview. Methods: This multi-center, randomized, patient- and assessor-blind, parallel-group trial was conducted in 14 community pharmacies in Vienna, Austria. Adult outpatients taking ≥8 drugs were eligible. The intervention was a medication review type 2a. At baseline, pharmacists assessed drug-related problems (DRP), a parameter summarizing problematic aspects of pharmacotherapy, in all participants. Pharmacists randomized patients (1, 1) to the intervention, in which they addressed DRPs, or to the control group, in which DRPs were not addressed. A blind pharmacist reassessed DRPs at the second visit after 3-4 months. The primary endpoint was the difference in the number of DRPs between groups after 3-4 months. Secondary endpoints included changes in therapy adherence, health literacy, and number of active ingredients per patient. Results: Between August 2022 and August 2023, 220 patients (intervention Conclusion: A medication review type 2a effectively reduced the number of DRPs. Trial registration: ISRCTN14052916.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.